This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Toogood, A. A. Articles by Shalet, S. M. Search for Related Content PubMed PubMed Citation Articles by Toogood, A. A. Articles by Shalet, S. M.

Preservation of Growth Hormone Pulsatility Despite Pituitary Pathology, Surgery, and Irradiation¹

Department of Endocrinology, Christie Hospital (A.A.T., S.M.S.), Withington, Manchester, United Kingdom M20 4BX; the Department of Medicine, University of Virginia Health Science Center (R.M.N., S.S.P., M.O.T.), Charlottesville, Virginia 22908; and the University Department of Geriatric Medicine, South Manchester University Hospital Trust (P.A.O.), Manchester, United Kingdom M20 2LR

Address all correspondence and requests for reprints to: Dr. Stephen M. Shalet, Department of Endocrinology, Christie Hospital, Withington, Manchester, United Kingdom M20 4BX.

Abstract

Detailed assessment of physiological and pathophysiological GH secretion has, until recently, been limited by the poor sensitivity of the available assays. We have used an ultrasensitive chemiluminescence GH assay (sensitivity, 0.002 µg/L) to study 24-h GH profiles (20-min sampling) from 24 patients who had been treated for hypothalamic-pituitary disease with surgery and irradiation and from 24 healthy control subjects matched for age, sex, and body mass index.

Twenty-three of the 24 patients demonstrated pulsatile GH secretion, determined by Cluster. The median (range) area under the curve for GH, mean pulse area, mean pulse height, average valley mean level, and mean interpeak nadir were lower in the patients than in the controls [119.25 (7.273–843.600) vs. 968.539 (227.200–4625.000) min/µg·L (P < 0.00001); 3.777 (0.288–30.850) vs. 61.390 (12.880–224.210) min/µg·L (P < 0.00001), 0.107 (0.010–0.958) vs. 1.408 (0.368–5.050) µg/L (P < 0.00001), 0.074 (0.006–0.415) vs. 0.348 (0.048–2.350) µg/L (P < 0.00001), and 0.066 (0.003–0.270) vs. 0.205 (0.021–1.838) µg/L (P = 0.0004), respectively]. The median (range) number of pulses, mean pulse duration, and mean interval between pulses did not differ between the patients and controls [10 (4–15) vs. 10 (7–15; P = 0.36), 96.4 (68.0–220.0) vs. 104.0 (72.0–151.4) min (P = 0.65) and 128.0 (92.8–255.0) vs. 126.2 (90.0–180.0) min (P = 0.73), respectively]. The diurnal rhythm of GH secretion was present in the controls, but there was only limited evidence of residual diurnal rhythm in the patients.

This study has demonstrated that GH secretion remains pulsatile in GH-deficient patients despite the mass effect of hypothalamic-pituitary pathology, pituitary surgery, and radiotherapy. With the development of potent GH secretagogues that are active orally, our findings may have important implications for the future management of GH-deficient subjects.

This article has been cited by other articles:

				J. Svensson, G. Johannsson, A. Iranmanesh, K. Albertsson-Wikland, J. D Veldhuis, and B.-A. Bengtsson GH secretory pattern in young adults who discontinued GH treatment for GH deficiency and decreased longitudinal growth in childhood. Eur. J. Endocrinol., July 1, 2006; 155(1): 91 - 99. [Abstract] [Full Text] [PDF]

				K. H. Darzy, R. D. Murray, H. K. Gleeson, S. S. Pezzoli, M. O. Thorner, and S. M. Shalet The Impact of Short-Term Fasting on the Dynamics of 24-Hour Growth Hormone (GH) Secretion in Patients with Severe Radiation-Induced GH Deficiency J. Clin. Endocrinol. Metab., March 1, 2006; 91(3): 987 - 994. [Abstract] [Full Text] [PDF]

				K. H. Darzy, S. S. Pezzoli, M. O. Thorner, and S. M. Shalet The Dynamics of Growth Hormone (GH) Secretion in Adult Cancer Survivors with Severe GH Deficiency Acquired after Brain Irradiation in Childhood for Nonpituitary Brain Tumors: Evidence for Preserved Pulsatility and Diurnal Variation with Increased Secretory Disorderliness J. Clin. Endocrinol. Metab., May 1, 2005; 90(5): 2794 - 2803. [Abstract] [Full Text] [PDF]

				M. L. Hartman, B. J. Crowe, B. M. K. Biller, K. K. Y. Ho, D. R. Clemmons, and J. J. Chipman Which Patients Do Not Require a GH Stimulation Test for the Diagnosis of Adult GH Deficiency? J. Clin. Endocrinol. Metab., February 1, 2002; 87(2): 477 - 485. [Abstract] [Full Text] [PDF]

				S. R. Peacey, A. A. Toogood, J. D. Veldhuis, M. O. Thorner, and S. M. Shalet The Relationship between 24-Hour Growth Hormone Secretion and Insulin-Like Growth Factor I in Patients with Successfully Treated Acromegaly: Impact of Surgery or Radiotherapy J. Clin. Endocrinol. Metab., January 1, 2001; 86(1): 259 - 266. [Abstract] [Full Text]

				H.E. Turner and J.A.H. Wass Modern approaches to treating acromegaly QJM, January 1, 2000; 93(1): 1 - 6. [Full Text] [PDF]

				A. A. Toogood and S. M. Shalet Growth Hormone Replacement Therapy in the Elderly with Hypothalamic-Pituitary Disease: A Dose-Finding Study J. Clin. Endocrinol. Metab., January 1, 1999; 84(1): 131 - 136. [Abstract] [Full Text]

				M. S. Gill, A. A. Toogood, P. A. O’Neill, M. O. Thorner, S. M. Shalet, and P. E. Clayton Urinary Growth Hormone (GH), Insulin-Like Growth Factor I (IGF-I), and IGF-Binding Protein-3 Measurements in the Diagnosis of Adult GH Deficiency J. Clin. Endocrinol. Metab., July 1, 1998; 83(7): 2562 - 2565. [Abstract] [Full Text]

				S. R. Peacey, A. A. Toogood, and S. M. Shalet Hypothalamic Dysfunction in "Cured" Acromegaly Is Treatment Modality Dependent J. Clin. Endocrinol. Metab., May 1, 1998; 83(5): 1682 - 1686. [Abstract] [Full Text]

				S. M. Shalet, A. Toogood, A. Rahim, and B. M. D. Brennan The Diagnosis of Growth Hormone Deficiency in Children and Adults Endocr. Rev., April 1, 1998; 19(2): 203 - 223. [Abstract] [Full Text]